JAK1 and colorectal carcinoma: Furthermore, combining CDN with the JAK1/2 inhibitor upadacitinib synergistically enhanced apoptosis and suppressed proliferation in CRC cells, supporting the functional relevance of JAK1/2 dual inhibition.